| Range: | 0.93-79.02 | Vol Avg: | 3054140 | Last Div: | 0 | Changes: | 2.95 |
| Beta: | 1.13 | Cap: | 0.25B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Mar 22 2021 | Empoloyees: | |||
| CUSIP: | 10919W108 | CIK: | 0001827401 | ISIN: | CA10919W4056 | Country: | CA |
| CEO: | Mr. Ian McDonald | Website: | https://brightmindsbio.com | ||||
DRUG 0.00 Stock Price Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow